Key Operating Metrics - Global studios increased by 8% year-over-year, reaching 3,066[13] - Global licenses increased by 3% year-over-year, totaling 5,318[13] - System-wide sales in North America increased by 10% year-over-year, reaching $432 million[14] - Run-Rate AUV in North America increased by 2% year-over-year, reaching $668,000[14] - Same-store sales increased by 7% year-over-year for studios open greater than 36 months[21] - Total members decreased by 1% to 796,000[21] Financial Performance - Revenue decreased by 2% year-over-year to $79 million[25] - Adjusted EBITDA increased by 9% year-over-year to $33 million, with a margin of 42% compared to 38% in the previous year[25, 33] - Adjusted net earnings per share - diluted is $034, compared to ($005) in Q3 2024[30] Future Outlook (FY 2025 Guidance) - The company anticipates between 170 and 190 net new studio openings globally, a -37% change vs 2024[35] - System-wide sales in North America are projected to be between $173 billion and $175 billion, a 12% increase compared to 2024[35] - Revenue is expected to be between $300 million and $310 million, a -5% change vs 2024[35] - Adjusted EBITDA is projected to be between $106 million and $111 million, a -7% change vs 2024[35]

Financial Performance - Q3 2025 revenue reached approximately $592 million, a year-over-year increase of about 35% compared to approximately $440 million in Q3 2024[8] - Approximately 894,000 total tests were processed in Q3 2025, reflecting a year-over-year growth of about 15% from approximately 776,000 in Q3 2024[8] - Clinical MRD tests numbered approximately 202,000 in Q3 2025, a year-over-year increase of about 56% from approximately 130,000 in Q3 2024[8] - Gross margin was approximately 65% in Q3 2025, with approximately $26 million in cash inflow generated[8] - The 2025 financial outlook was increased by $160 million, projecting revenue between $218 billion and $226 billion, gross margin between 62% and 64%, and $100 million in cash flow generation[8] Product Development and Data - A newly expanded 20-gene panel for Fetal Focus is launching in Q4[29] - Early cancer detection data for advanced adenomas was announced[8] - Strong Signatera data was presented at ESMO, reinforcing MRD leadership[8] Clinical Data and Studies - ESMO Congress presented practice-changing evidence in muscle-invasive bladder cancer[33] - Strong Signatera data in colorectal cancer was presented at ESMO, with a publication in Nature[36] - Overall advanced adenoma performance showed 225% sensitivity (CI: 154%-324%) and 915% specificity (CI: 882%-939%)[44]

Third Quarter 2025 © 2025 RB Global, Inc. | All Rights Reserved Forward-Looking Statements Forward-Looking Statements: Certain statements contained in this presentation include "forward-looking statements" within the meaning of U.S. federal securities laws and "forward-looking information" within the meaning of Canadian securities laws (collectively, "forward-looking statements"). Forward-looking statements herein include, in particular statements relating to future financial and operational results, opport ...

Financial Performance - Q3 2025 - Consolidated Revenue reached $468 million, a 3.5% year-over-year increase[5] - Transit Revenue experienced significant growth, rising by 23.7% to $112 million[5] - Consolidated Operating Income increased substantially by 26.1% to $90 million[5] - Consolidated Adjusted OIBDA grew by 17.2% to $137 million[5] - Consolidated Net Income saw a considerable increase of 48.3% to $51 million[5] - Consolidated AFFO (Adjusted Funds From Operations) increased by 24.1% to $100 million[5] Billboard Segment Performance - Billboard Revenue decreased slightly by (2.2%) to $353 million[5] - Billboard Adjusted OIBDA increased modestly by 2.1% to $139 million[5] Factors Affecting Comparability - NY MTA Billboard Contract: Q3'25 revenue was $0.0 million compared to $7.7 million in Q3'24[7] - LA Billboard Contract: Q3'25 revenue was $0.0 million compared to $5.1 million in Q3'24[7] Digital Revenue Growth - Digital revenues accounted for 35.6% of total Billboard & Transit revenues in Q3 2025, up from 32.7% in Q3 2024[58]

Q3 2025 Performance - Consumables revenue reached $285 million in Q3 2025, representing an 8% year-over-year growth[8] - Systems revenue increased to $174 million in Q3 2025, a 9% year-over-year increase[8] - Vital Care revenue declined significantly to $74 million in Q3 2025, a 52% year-over-year decrease[8] - Total ICU Medical revenue was $533 million in Q3 2025, reflecting an 8% year-over-year decrease[8] 2025 Guidance Update (Post JV Transaction) - Adjusted EBITDA is projected to be between $395 million and $405 million[9] - Adjusted EPS is expected to be between $735 and $765[9] - Consolidated revenue is expected to have a ~ (6%) FXN impact, with low to mid single digits organic growth[9] - Vital Care is expected to have a ~ (35%) FXN impact, with flat organic growth[9] - Net interest expenses are projected to be around $19 million in Q4[9] - Capital expenditures are estimated to be between $85 million and $95 million[9]

Q3 2025 Performance Highlights - Total revenue reached $286 million[8] - Adjusted EBITDA margin was 25%[8, 12] - Free cash flow margin was 13%[8, 12] - Dollar Based Retention Rate (DBRR) was 107%[8, 12] AI Metrics in Q3 2025 - Enterprise AI revenue experienced year-over-year growth of 41%[13] - AI contributed 11% to enterprise subscription revenue[13] - Enterprise AI bookings grew by over 80% year-over-year[13] - AI accounted for over 20% of enterprise new logo ACV bookings[13] - AI was virtually always attached to $1M+ ARR new logo deals[13] Financial Guidance and Share Repurchase Program - The company authorized a $150 million share repurchase program expiring on December 31, 2027[9, 11] - An Accelerated Share Repurchase (ASR) agreement is intended to repurchase $50 million of common stock, with final settlement expected by the end of Q1 2026[11] - Q4 2025 revenue is projected to be between $2947 million and $300.7 million[36] - Full-year 2025 revenue is guided to be between $1.1435 billion and $1.1495 billion[36]

Financial Performance - Total revenue reached $27.0 million, representing a 7.3% year-over-year decrease compared to $35.187 million in Q3 2024 [32] - Service revenue increased by 35.5% year-over-year, reaching $11.863 million in Q3 2025 compared to $8.754 million in Q3 2024 [32] - Gross profit increased by 6.0% to $9.666 million in Q3 2025 from $9.119 million in Q3 2024 [32] - Gross margin was 35.8% in Q3 2025, with product gross margin at 39%, a ~700 bps year-over-year increase [18] - Adjusted EBITDA improved by 36.7% to -$8.867 million in Q3 2025, compared to -$14.017 million in Q3 2024 [32] Operational Highlights - Cash burn reduced by 87% to $2.2 million in Q3 2025 [11] - Operating expenses decreased by 89.9% to $9.871 million in Q3 2025 from $97.345 million in Q3 2024 [32] - Network fees grew by 36% year-over-year [22] - Charging revenue from US Blink owned DC chargers grew by 339% year-over-year [22] - The company improved working capital by $5 million in Q3 2025 [10]

Earnings Q3 2025 November 2025 Disclaimer This presentation is made by OneStream, Inc. (the "Company," "we," "our" or "we") and contains forward -looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this presentation may be forward -looki ng statements. In some cases, you can identify forward - looking statements by terms such as "may," "will," "should," "expects," "plans," "anticipates," "could," ...

Puma Biotechnology Earnings Call Commercial Update Puma's Pharmacy and Distributor Network Copyright 2025 Puma Biotechnology 3 November 6, 2025 Forward-Looking Safe-Harbor Statement This presentation contains forward-looking statements, including statements regarding commercialization of NERLYNX® and the potential indications and development of our drug candidates. All forward-looking statements involve risks and uncertainties that could cause our actual results to differ materially from the anticipated res ...

Financial Performance - Sales increased by 8.6% to $513.7 million in Q3 2025, compared to $472.9 million in Q3 2024[7] - Organic sales grew 11.5% year-over-year[7] - Acquisition sales contributed $18.4 million to total sales[7] - Net income increased 2.5% to $21.6 million for the third quarter, compared to $21.1 million for the third quarter of 2024[7] - Earnings per diluted share increased to $1.31, based on 16.5 million diluted shares, compared to $1.27 in Q3 2024, based on 16.6 million diluted shares[7] - Cash flow from operating activities increased 23.1% to $34.9 million, compared to $28.3 million in Q3 2024[7] - Free Cash Flow increased 15.4% to $28.1 million, compared to $24.4 million in Q3 2024[7] - Adjusted EBITDA was $56.5 million, compared to $52.4 million for the third quarter of 2024[7] - Adjusted EBITDA margin was 11.0%, compared to 11.1% respectively[7] Strategic Actions - The company closed one acquisition during the third quarter and two subsequent to quarter end[7]